FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to dermatology. That is ensured by topically applying a pharmaceutical composition containing 0.001 % to 0.20 % by weight of a prostaglandin F2-alpha (PGF 2α), PGF 2α analogue, selected from latanoprost, travoprost, bimatoprost or tafluprost or combinations thereof, and a pharmaceutically acceptable carrier directly on an area of atrophic cicatrisation.
EFFECT: invention can be used for treating atrophic cutaneous scar in a human.
8 cl, 3 dwg, 1 ex
